CA
NGNE icon

Clearstead Advisors’s Neurogene NGNE Stock Holding History

Clearstead Advisors’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$32 Buy
+1
New +$28 ﹤0.01% 3541

Other funds holding NGNE

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
RBI
Raiffeisen Bank International Vienna, Austria $8.53B AUM 46.94% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $609B AUM 40.19% 1-Year Est. Return
QC
Quadrature Capital London, United Kingdom $11.7B AUM 87.29% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 23.41% 1-Year Est. Return
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Mitsubishi UFJ Asset Management
Mitsubishi UFJ Asset Management Tokyo, Japan $180B AUM 37.51% 1-Year Est. Return

Clearstead Advisors's NGNE Position: Q2 2026 in Review

Clearstead Advisors opened a new position in Neurogene (NGNE) in Q2 2026: 1 share worth $32. The stake represents ﹤0.01% of the portfolio and ranks #3541 among its holdings.

32 funds tracked by Wall St. Rank hold NGNE as of Q2 2026.

  • Clearstead Advisors held 1 share of Neurogene worth $32 as of Q2 2026.
  • Neurogene was a new Clearstead Advisors position in Q2 2026.
  • Neurogene made up ﹤0.01% of Clearstead Advisors's portfolio in Q2 2026, its #3541 holding.
  • 32 funds tracked by Wall St. Rank held Neurogene as of Q2 2026.

Based on Clearstead Advisors's 13F filing for Q2 2026, filed 6 Aug 2026.